CHD1L and neoplasm: Sub-dividing tumors into three different categories (lymphomas, epithelial, or mesenchymal; Table 1) revealed that although lymphoma-free survival (median survival time: 734 days for Alc1−/− versus 755 days for Alc1+/+; Figure S1I, left panel) and incidence of lymphomas (Figure S1I, right panel) are similar in Alc1+/+ and Alc1−/− mice, epithelial or mesenchymal tumor-free survival tended to be increased in Alc1−/− mice (734 days for mice lacking ALC1 versus 671 days for their WT littermates; Figure 1D, left panel; Figure S1J).